Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.57 |
| ▸ | CCNK | O75909 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19867185 | 0.88 | ALK (0.63) | ALKCDK2PTK2JAK2BRD4 | |
| SCHEMBL21099812 | 0.87 | CCND3 (0.54) | ALKCCNKCCNA2CDK2CCND3 | |
| SCHEMBL19867212 | 0.85 | ALK (0.61) | ALKPTK2JAK2BRD4EGFR | |
| SCHEMBL21100192 | 0.85 | ALK (0.65) | ALKCDK2PTK2JAK2BRD4 | |
| SCHEMBL28881275 | 0.83 | CCNK (0.77) | ALKCCNKCCNA2CDK2CCND3 | |
| SCHEMBL19867326 | 0.82 | ALK (0.52) | ALKPTK2JAK2BRD4IRAK4 | |
| SCHEMBL21150115 | 0.82 | ALK (0.63) | ALKCDK2CDK9PTK2JAK2 | |
| SCHEMBL19867369 | 0.78 | ALK (0.60) | ALKCCNKCDK2CCND3CDK9 | |
| SCHEMBL19867368 | 0.77 | PDE5A (0.56) | ALKPTK2JAK2BRD4AXL | |
| SCHEMBL19867189 | 0.77 | ALK (0.84) | ALKCDK2PTK2JAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885CCNK 271/4885CCNA2 1081/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885CCNK 271/4885CCNA2 1081/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | ALK 1/4885CCNK 271/4885CCNA2 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.